NeuroTherapia Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 3

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $12.3M

  • Investors
  • 9

NeuroTherapia General Information

Description

Developer of cannabinoid receptor agonists designed to treat diseases associated with neuroinflammation. The company develops drugs that modulate microglial cell activity to reduce brain inflammation and neuronal injury, enabling pharmaceutical researchers and healthcare providers to explore potential treatments for Alzheimer's disease and neuropathic pain.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • PO Box 351
  • 1500 Chagrin River Road
  • Gates Mills, OH 44040
  • United States
+1 (440)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Vertical(s)
Corporate Office
  • PO Box 351
  • 1500 Chagrin River Road
  • Gates Mills, OH 44040
  • United States
+1 (440)

NeuroTherapia Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

NeuroTherapia Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series B) 06-Aug-2024 $12.3M Completed Clinical Trials - Phase 2
4. Later Stage VC (Series A) 22-Sep-2020 Completed Clinical Trials - Phase 2
3. Grant 21-Sep-2016 Completed Clinical Trials - Phase 2
2. Grant 08-Sep-2026 $2.3M Completed Clinical Trials - Phase 2
1. University Spin-Out 13-Oct-2015 $1M Completed Startup
To view NeuroTherapia’s complete valuation and funding history, request access »

NeuroTherapia Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B-2
Series B-1
Series A 8,773,899 $0.001000 $0.05 $1 $1 1x $1 35.29%
To view NeuroTherapia’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

NeuroTherapia Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of cannabinoid receptor agonists designed to treat diseases associated with neuroinflammation. The company dev
Drug Discovery
Gates Mills, OH
3 As of 2026

Miami, FL
 

Durham, NC
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

NeuroTherapia Competitors (6)

One of NeuroTherapia’s 6 competitors is ADvantage Therapeutics, a Venture Capital-Backed company based in Miami, FL.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
ADvantage Therapeutics Venture Capital-Backed Miami, FL
T3D Therapeutics Venture Capital-Backed Durham, NC
Alector Formerly VC-backed South San Francisco, CA
LeonaBio Formerly VC-backed Bothell, WA
Verge Labs Venture Capital-Backed San Francisco, CA
To view NeuroTherapia’s complete competitors history, request access »

NeuroTherapia Patents

NeuroTherapia Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2024335816-A1 Methods of treating cognitive impairment Pending 07-Sep-2023
EP-4773962-A1 Methods of treating cognitive impairment Pending 07-Sep-2023
US-20250082624-A1 Methods of treating cognitive impairment Pending 07-Sep-2023
WO-2025054408-A1 Methods of treating cognitive impairment Inactive 07-Sep-2023 A61K31/4525

NeuroTherapia Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

NeuroTherapia Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
National Institute on Aging Government
CRU Clinical Research Units Corporation Minority
Foundation For a Better World Corporation Minority
PMK-Group Venture Capital Minority
Alzheimer's Association Corporation Minority
You’re viewing 5 of 9 investors. Get the full list »

NeuroTherapia FAQs

  • When was NeuroTherapia founded?

    NeuroTherapia was founded in 2015.

  • Where is NeuroTherapia headquartered?

    NeuroTherapia is headquartered in Gates Mills, OH.

  • What is the size of NeuroTherapia?

    NeuroTherapia has 3 total employees.

  • What industry is NeuroTherapia in?

    NeuroTherapia’s primary industry is Drug Discovery.

  • Is NeuroTherapia a private or public company?

    NeuroTherapia is a Private company.

  • What is the current valuation of NeuroTherapia?

    The current valuation of NeuroTherapia is .

  • What is NeuroTherapia’s current revenue?

    The current revenue for NeuroTherapia is .

  • How much funding has NeuroTherapia raised over time?

    NeuroTherapia has raised $20.8M.

  • Who are NeuroTherapia’s investors?

    National Institute on Aging, CRU Clinical Research Units, Foundation For a Better World, PMK-Group, and Alzheimer's Association are 5 of 9 investors who have invested in NeuroTherapia.

  • Who are NeuroTherapia’s competitors?

    ADvantage Therapeutics, T3D Therapeutics, Alector, LeonaBio, and Verge Labs are some of the 6 competitors of NeuroTherapia.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process